Global biotech firm GenScript has officially opened its first European mRNA production facility in Delft, marking a major expansion of the company's global mRNA platform and cementing Europe as a central hub in its integrated R&D and manufacturing network.

 

The new Delft site strengthens GenScript’s transatlantic biotech infrastructure, offering regional proximity, regulatory alignment, and supply chain resilience for European developers of next-generation therapies, vaccines, and advanced biologics.

 

"Having a local GenScript facility in the EU makes a real difference for us," said Paula Río, of Hematopoietic Innovative Therapies Unit, CIEMAT/CIBERER/FJD, UAM. "The closer proximity enables more seamless collaboration, faster turnaround times, and reduced shipping delays. Working with a team that's fully aligned with EU regulations and standards strengthens the partnership and makes day‑to‑day interactions significantly easier."

 

For GenScript, the Delft facility is more than a regional outpost—it is a fully integrated node in the company’s global platform strategy. The U.S.-founded biotech, established in New Jersey over 20 years ago, continues to expand across North America and Europe through disciplined investments in scalable, customer-ready infrastructure.

 

"Europe is not an outpost in our network; it is a core pillar of our global mRNA platform," said Shawn Wu, President of GenScript EU Division. "By integrating Delft into our unified global operating system, we are delivering greater speed, regulatory alignment, and operational resilience for our partners, while maintaining one uncompromising global standard."

 

Located within one of Europe’s strongest life science ecosystems, the Delft facility offers a complete mRNA workflow, including: Gene design and synthesis; Vector engineering; IVT mRNA production; Proprietary GenCap mRNA capping technology.

 

The Delft launch complements ongoing expansion at GenScript’s New Jersey campus and the company’s broader operations across North America, Europe, and Asia. These coordinated investments reflect GenScript’s strategy to build resilient, high-quality growth platforms that support innovation from early discovery through advanced development.

 

"From our first conversations, GenScript has demonstrated a strong commitment to innovation, collaboration, and scientific excellence," said Cindy Gerhardt, Managing Director of Planet B.io. 

 

"We've built a valuable partnership driven by a shared ambition to accelerate biotech research and innovation. The opening of this state-of-the-art lab strengthens the position of the Biotech Campus Delft—not only for our own community, but for the broader European biotech ecosystem."

 

"This expansion reflects disciplined execution of our global platform strategy," said Sherry Shao, CEO of GenScript Biotech Corporation.